Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 25:17:11-14.
doi: 10.2147/BTT.S394843. eCollection 2023.

Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis

Jolijn R van Leeuwen #  1 , Tamara Popov #  2 , Achim Obergfell  2 , Ton J Rabelink  1 , Y K Onno Teng  1
Affiliations

Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis

Jolijn R van Leeuwen et al. Biologics. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Achim Obergfell is a shareholder of Vifor Pharma. YK Onno Teng has received an unrestricted research grant and consultancy fees from Vifor Pharma. The work of YK Onno Teng is supported by the Dutch Kidney Foundation (17OKG04) and by the Arthritis Research and Collaboration Hub (ARCH) foundation. ARCH is funded by Dutch Arthritis Foundation (ReumaNederland). The authors report no other conflicts of interest in this work.

References

    1. Yates M, Watts R. ANCA-associated vasculitis. Clin Med. 2017;17(1):60–64. doi:10.7861/clinmedicine.17-1-60 - DOI - PMC - PubMed
    1. Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756–2767. doi:10.1681/ASN.2016111179 - DOI - PMC - PubMed
    1. Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599–609. doi:10.1056/NEJMoa2023386 - DOI - PubMed
    1. Vifor Pharma press releases. VFMCRP receives EU approval for Tavneos® for the treatment of ANCA associated vasculitis; 2022. Available from: https://www.viforpharma.com/sites/vifor-corp/files/media/vifor-pharma-pr.... Accessed October 6, 2022.
    1. van Leeuwen JR, Bredewold OW, van Dam LS, et al. Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep. 2022;7(3):624–628. doi:10.1016/j.ekir.2021.11.036 - DOI - PMC - PubMed